<DOC>
	<DOC>NCT01072266</DOC>
	<brief_summary>This is an open label, dose escalation study using a 3 + 3 design to determine if INCB028060 (study drug) is safe, well-tolerated and effective in patients with advanced malignancies. Patients will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group is enrolled and may begin to receive study drug. Doses will be escalated unless a dose-limiting toxicity (DLT) is observed in one of three subjects.</brief_summary>
	<brief_title>A Dose-escalation Study in Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Subjects with neoplastic disease refractory to currently available therapies or for which no effective treatment is available Subjects with life expectancy of 12 weeks or longer. Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Subjects who received any anticancer medications in the 21 days prior to receiving their first dose of study medication or 6 weeks for mitomycinC or nitrosoureas. Subjects with history of brain metastases or spinal cord compression. Subjects who have undergone a bone marrow or solid organ transplant. Subjects who have had major surgery within 4 weeks prior to study entry or had minor surgical procedure within 7 days prior to initiating treatment. Subjects with clinically significant nonhealing or healing wounds or subjects with lung tumor lesions with increased likelihood of bleeding Subjects with a history of any gastrointestinal condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Refractory, Advanced malignancies</keyword>
</DOC>